Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL)
CUSIP: 98943L107
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock,$0.001 par value per share
- Shares outstanding
- 72,096,078
- Total 13F shares
- 55,655,238
- Share change
- -2,898,178
- Total reported value
- $64,573,024
- Price per share
- $1.16
- Number of holders
- 115
- Value change
- -$4,209,380
- Number of buys
- 54
- Number of sells
- 81
Quarterly Holders Quick Answers
What is CUSIP 98943L107?
CUSIP 98943L107 identifies ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 98943L107:
Top shareholders of ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Anthony Y. Sun |
3/4/5
|
President & CEO, Director |
—
class O/S missing
|
2,592,141
|
$26,672,095 | — | 04 Apr 2022 | |
| Matrix Capital Management Company, LP |
13F
|
Company |
19%
|
13,959,973
|
$22,196,357 | — | 31 Mar 2025 | |
| Iris Roth |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
350,000
mixed-class rows
|
$14,760,704 | — | 01 Mar 2023 | |
| Walters William T. |
13D/G
|
— |
9.9%
|
7,050,000
|
$10,081,500 | +$786,500 | 29 Jan 2025 | |
| Kevin D. Bunker |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
850,281
|
$8,749,051 | — | 20 Dec 2023 | |
| Cam Gallagher |
3/4/5
|
President, Interim CFO, Director |
—
mixed-class rows
|
826,180
mixed-class rows
|
$7,591,486 | — | 31 May 2024 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
2.2%
from 13D/G
|
4,229,497
|
$6,724,900 | — | 31 Mar 2025 | |
| Kimberly Blackwell |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
734,145
mixed-class rows
|
$5,659,655 | — | 01 Feb 2024 | |
| VANGUARD GROUP INC |
13F
13D/G
|
Company · The Vanguard Group |
4.6%
from 13D/G
|
3,260,612
|
$5,184,373 | — | 31 Mar 2025 | |
| Melissa B. Epperly |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
526,449
mixed-class rows
|
$5,164,577 | — | 12 Feb 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
4.3%
|
3,069,514
|
$4,880,527 | — | 31 Mar 2025 | |
| Diana F. Hausman |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
711,376
mixed-class rows
|
$4,718,315 | — | 09 May 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
3.7%
|
2,674,035
|
$4,244,000 | — | 31 Mar 2025 | |
| Decheng Capital LLC |
13F
|
Company |
2.8%
|
2,019,762
|
$3,211,422 | — | 31 Mar 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
2.8%
|
1,985,000
|
$3,156,150 | — | 31 Mar 2025 | |
| Almitas Capital LLC |
13F
|
Company |
2.4%
|
1,710,921
|
$2,720,364 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.1%
|
1,500,000
|
$2,385,000 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
1,355,669
|
$2,156,109 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
1,319,785
|
$2,098,458 | — | 31 Mar 2025 | |
| Alexis Pinto |
3/4/5
|
Chief Legal Officer |
—
mixed-class rows
|
60,729
mixed-class rows
|
$2,068,615 | — | 10 Feb 2022 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
1.8%
|
1,264,620
|
$2,010,746 | — | 31 Mar 2025 | |
| Andrea Paul |
3/4/5
|
Chief Legal Officer |
—
mixed-class rows
|
1,195,498
mixed-class rows
|
$1,832,647 | — | 03 Feb 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.6%
|
1,130,092
|
$1,796,847 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.6%
|
1,117,777
|
$1,777,266 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.5%
|
1,093,958
|
$1,739,392 | — | 31 Mar 2025 | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD |
13F
|
Company |
1.3%
|
961,486
|
$1,528,763 | — | 31 Mar 2025 | |
| PFIZER INC |
13F
|
Company |
1.3%
|
953,834
|
$1,516,596 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.2%
|
842,600
|
$1,339,734 | — | 31 Mar 2025 | |
| Dimitris Voliotis |
3/4/5
|
SVP, Clinical Development |
—
mixed-class rows
|
40,212
mixed-class rows
|
$1,322,792 | — | 10 Feb 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.1%
|
826,041
|
$1,313,405 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
1%
|
752,517
|
$1,196,502 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1%
|
746,476
|
$1,186,897 | — | 31 Mar 2025 | |
| Carrie Brownstein |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
105,685
|
$1,087,456 | — | 04 Oct 2023 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.86%
|
619,330
|
$984,734 | — | 31 Mar 2025 | |
| Peapod Lane Capital LLC |
13F
|
Company |
0.77%
|
558,418
|
$887,885 | — | 31 Mar 2025 | |
| Mark Lackner |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
637,570
mixed-class rows
|
$877,753 | — | 03 Feb 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.76%
|
549,334
|
$873,441 | — | 31 Mar 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.75%
|
541,975
|
$862,000 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.74%
|
530,582
|
$843,625 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.7%
|
507,527
|
$806,968 | — | 31 Mar 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.68%
|
490,000
|
$779,100 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.67%
|
486,499
|
$773,533 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.64%
|
462,303
|
$735,062 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.63%
|
456,393
|
$725,665 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.62%
|
447,400
|
$711,550 | — | 31 Mar 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.5%
|
361,236
|
$574,365 | — | 31 Mar 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.48%
|
348,965
|
$554,854 | — | 31 Mar 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.47%
|
341,388
|
$542,807 | — | 31 Mar 2025 | |
| Scott Dunseth Myers |
3/4/5
|
Director |
0.47%
|
338,795
|
$403,166 | +$29,373 | 17 Jun 2025 | |
| Creative Planning |
13F
|
Company |
0.33%
|
236,523
|
$376,072 | — | 31 Mar 2025 |
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) as of Q2 2025
As of 30 Jun 2025,
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) was held by
115 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,655,238 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, Opaleye Management Inc., BlackRock, Inc., Almitas Capital LLC, TANG CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, and TYBOURNE CAPITAL MANAGEMENT (HK) LTD.
This page lists
115
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
131
Q2 2025 holders
115
Holder diff
-16
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.